Imexhs Ltd · ASX:IME
Imexhs — Shareholder Meeting (May 2025)
41 slides from Imexhs's shareholder meeting presentation, May 19, 2025
Slide 1: 2025 Annual General Meeting – Chairman and CEO Addresses
19 May 2025 ASX ANNOUNCEMENT 2025 Annual General Meeting – Chairman and CEO Addresses In accordance with ASX Listing Rule 3.13, attached are the Chairman and CEO Addresses together with the presentation slides, which will be delivered at the IMEXHS Limited (ASX: IME) (Company) Annual General Meeting
Slide 2: Chairman's Address
IMEXHS Limited Annual General Meeting 19 May 2025 Chairman’s Address We are now well into 2025, and it is an exciting time for IMEXHS with the new value proposition software, Aquila+, now being sold and deployed. The development of Aquila+ has been, thus far, an exemplary project. It commenced at th
Slide 3: Chairman's Address: Software and RIMAB
Importantly the board and management understand that we need to drive software sales and revenue faster than we have been. Despite this, the company has made good progress in several areas. Software Our practice of pricing software in USD has been largely accepted and for the year ended December 202
Slide 4: Chairman's Address: RIMAB and Looking Ahead
RIMAB experienced significant inflationary cost drag entering into 2024 and has spent much of the first half renegotiating contract terms to improve the economics for us and still provide sound economics and great healthcare outcomes for our clients. RIMAB has also focussed closely on operating cost
Slide 5: CEO's Address
That said we appreciate the support and engagement of our shareholders and have sought to improve our communication, including detailed quarterly reporting. Your Directors and Management are highly conscious that they need to deliver on the promise this company holds. We look forward to 2025 with so
Slide 6: CEO's Address: Q1 2025 progress
We achieved positive commercial and operational progress in the first quarter of 2025. Aquila Plus generated strong market interest with two successful launch events with over 400 attendees, which engaged key partners and opened new distribution opportunities. Aquila plus is already installed across
Slide 7: CEO's Address: Aquila+ and software business
Across all these groups, our ISO 27001 and HIPAA-ready architecture ensures compliance and robust data security. Ultimately, faster and more accurate diagnoses mean better outcomes for patients and less time waiting for results. This is how Aquila+ is setting a new standard in medical imaging-clear,
Slide 8: Annual General Meeting
Annual General Meeting 19 May 2025
Slide 9: Board of Directors
Board of Directors Doug Flynn Carlos Palacio Dr Doug Lingard Damian Banks Dr German Arango Non-Executive Non-Executive Non-Executive Non-Executive CEO & Managing Chairman Director Director Director Director IMEXHS LTD (ASX:IME) | AGM 19 May 2025 2
Slide 10: Agenda
Agenda 2025 AGM 1. Introductions 2. Chairman’s Address 3. CEO’s Address 4. Business of Meeting 5. Resolutions & Proxy Vote Results 3
Slide 11: Chairman's Address
Chairman’s Address Doug Flynn
Slide 12: CEO's Address
CEO’s Address Dr German Arango
Slide 13: Management Team
Management Team Dr German Arango Reena Minhas Orlando Joven CEO & Managing Director Chief Financial Chief Operations Officer Officer Dr Jorge Marin Elizabeth Mendez Juan David Dr Sandra Chief Medical Officer Operations Manager & Fajardo Niño & Co-Founder Contract Audit VP of Global Sales Medical Dir
Slide 14: One Company with two businesses democratising access to medical imaging expertise
One Company with two businesses aimed at democratising access to medical imaging expertise Medical Imaging Software Radiology Services Provider of innovative, cloud-based, Outsourcing of imaging facilities AI medical imaging software and teleradiology to hospitals and solutions medical facilities 7
Slide 15: Global footprint
Global footprint Software 18 countries; 546 sites 3,539 radiologists 23 distributors in 16 countries Radiology Colombia, Spain and Mexico 36 radiology centres 160+ in-house radiologists 8
Slide 16: FY24 Financial Highlights
FY24 Financial Highlights1 Sales Revenue Annual Recurring Underlying Revenue (ARR) 3 EBITDA4 Up 34% yoy $26.5m Up 20% yoy $30.0m vs $0.2m5 in pcp Up 27% on a constant Up 24% on a constant currency basis2 currency basis $0.5m Recurring Closing cash Debt revenue 97% of total revenue $25.8m vs $2.4m at
Slide 17: Business Highlights FY25 Update
Business Highlights FY25 Update • Aquila+ made a high-impact debut with two • The Company is focused on generating positive launch events: Over 100 partners and potential earnings and cashflow. distributors joined our virtual event, while a live • Geographic attention remains within Latin stream att
Slide 18: New Value Proposition-Aquila+
New Value Proposition-Aquila+ Radiologists with Superpowers 1 Product. “The most advanced, contemporary and secure radiology AI enhanced software solution.” 2 Customer Service & Support. “Unparalleled customer support, setting a new industry standard.” 3 Implementation, Training & Updates. “The most
Slide 19: Transforming Medical Imaging: Delivering Tangible Value to every Stakeholder
Transforming Medical Imaging: Delivering Tangible Value to every Stakeholder Patients Referral Physicians Radiologists Healthcare Providers and Specialists and IMEXHS • Patients and physicians • Unified cloud platform • AI-powered tools • Redesigned benefit from secure, enables seamless and workflow
Slide 20: Focus for FY25
Focus for FY25 Software Radiology Services ● Roll out the New Value Proposition-Aquila+ ➢ Enhanced digital security: Achieve ISO ● Focus on profitability: successfully renegotiated 27001 certification key contracts with better pricing, improving ➢ Service excellence: Delivering the best margins in e
Slide 21: FY25 Outlook
FY25 Outlook H1 FY25 • Continuing momentum from go live of Key drivers for revenue and earnings recent contracts. growth: • Upfront launch costs for marketing and sales for Aquila+. • Annualised Recurring H2 FY25 Revenue together with current • Radiology Profit Improvement pipeline. Program through
Slide 22: Business of Meeting
ime<HS Business of Meeting
Slide 23: Resolutions & Proxy Vote Results
Resolutions & Proxy Vote Results
Slide 24: Financial Report
Financial Report To receive the financial report of the Company and the reports of the Directors and of the Auditors for the financial year ended 31 December 2024. Q&A
Slide 25: Resolution 1: Remuneration Report
Resolution 1: Remuneration Report “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 31 December 2024 as disclosed in the Company’s Annual Report be adopted.” Proxy votes For Against Open 9,964,652 111,6
Slide 26: Resolution 2: Re-election of Director – Mr Carlos Palacio
Resolution 2: Re-election of Director – Mr Carlos Palacio “That, for the purpose of Article 6.3(c) of the Constitution, ASX Listing Rule 14.4 and 14.5, and for all other purposes, Mr Carlos Palacio, a Director, retires by rotation, and being eligible, is re-elected as a Director of the Company Proxy
Slide 27: Resolution 3: Grant of Options to the Chief Executive Officer
Resolution 3: Grant of Options to the Chief Executive Officer “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 175,810 Options to the Managing Director & CEO, Dr German Arango, under the Plan on the terms and conditions set out in the Ex
Slide 28: Resolution 4: Grant of Options to Non-Executive Director Mr Damian Banks
Resolution 4: Grant of Options to Non-Executive Director Mr Damian Banks “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 37,356 Options to Non-Executive Director, Mr Damian Banks, under the Plan on the terms and conditions set out in th
Slide 29: Resolution 5: Grant of Options to Non-Executive Director Mr Douglas Flynn
Resolution 5: Grant of Options to Non-Executive Director Mr Douglas Flynn “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 74,711 Options to Non-Executive Director, Mr Douglas Flynn, under the Plan on the terms and conditions set out in
Slide 30: Resolution 6: Grant of Options to Non-Executive Director Dr Doug Lingard
Resolution 6: Grant of Options to Non-Executive Director Dr Doug Lingard “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 37,356 Options to Non-Executive Director, Dr Doug Lingard, under the Plan on the terms and conditions set out in th
Slide 31: Resolution 7: Grant of Options to Non-Executive Director Mr Carlos Palacio
Resolution 7: Grant of Options to Non-Executive Director Mr Carlos Palacio “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 37,356 Options to Non-Executive Director, Mr Carlos Palacio, under the Plan on the terms and conditions set out i
Slide 32: Resolution 8: Approval of 10% Share Placement Capacity
Resolution 8: Approval of 10% Share Placement Capacity "That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the Company having additional capacity to issue Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) (10% Sh
Slide 33: Resolution 9: Ratification of Prior Issue of Securities – Placement
Resolution 9: Ratification of Prior Issue of Securities – Placement “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, the Shareholders ratify the issue on 14 April 2025 of a total of 4,285,712 fully paid ordinary shares in the Company at an issue price of $0.35 per share un
Slide 34: Resolution 10: Issue of Shares to Mr Douglas Flynn under Conditional Placement
Resolution 10: Approval of Issue of Shares to Mr Douglas Flynn under the Conditional Placement “That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 471,429 fully paid ordinary shares in the Company at $0.35 per fully paid ordinary share to D
Slide 35: Resolution 11: Issue of Shares to Mr Carlos Palacio under Conditional Placement
Resolution 11: Approval of Issue of Shares to Mr Carlos Palacio under the Conditional Placement “That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 328,572 fully paid ordinary shares in the Company at $0.35 per fully paid ordinary share to
Slide 36: Resolution 12: Issue of Shares to Mr Douglas Lingard under Conditional Placement
Resolution 12: Approval of Issue of Shares to Mr Douglas Lingard under the Conditional Placement “That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 542,858 fully paid ordinary shares in the Company at $0.35 per fully paid ordinary share to
Slide 37: Resolution 13: Issue of Shares to Mr Damian Banks under Conditional Placement
Resolution 13: Approval of Issue of Shares to Mr Damian Banks under the Conditional Placement “That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 328,572 fully paid ordinary shares in the Company at $0.35 per fully paid ordinary share to HS
Slide 38: Resolution 14: Issue of Shares to Dr German Arango under Conditional Placement
Resolution 14: Approval of Issue of Shares to Dr German Arango under the Conditional Placement “That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 328,572 fully paid ordinary shares in the Company at $0.35 per fully paid ordinary share to D
Slide 39: Resolution 15: Conditional Spill Resolution
Resolution 15: Conditional Spill Resolution Subject to and conditional on at least 25% of the votes cast on Resolution 1 being cast against Resolution 1, to consider, and if thought fit, to pass the following resolution as an ordinary resolution: “That: a) another meeting (the Spill Meeting) of the
Slide 40: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co
Slide 41: Annual General Meeting
Annual General Meeting 19 May 2025